The National Cancer Institute's Office of Cancer Genomics – Advancing Precision Medicine through Cutting-Edge Cancer Genomics and Functional Biology Research

Wednesday, September 24, 2014 — Poster Session IV
10:00 a.m. –12:00 p.m.	FAES Academic Center	NCI	CANCER-11

Authors

• S. Jagu
• J.N. Mazerik
• S.L. Behrman
• J.M. Guidry Auvil
• N.B. Griner
• M. Ferguson
• T. Calder
• D.S. Gerhard

Abstract

The National Cancer Institute’s Office of Cancer Genomics (OCG) supports collaborative genomics and functional biology research initiatives to advance the development of precision medicine. Precision medicine provides a potentially more effective, less toxic patient-based approach to medicine by identifying the molecular features of an individual patient’s disease and tailoring clinical practices and therapies to those features. OCG researchers are uncovering the genomic and molecular changes that drive cancer initiation and progression in patient tumors, and determining which alterations may be therapeutically targeted or used as predictive/prognostic biomarkers to guide better treatments. Current OCG research initiatives: 1. The Cancer Genome Characterization Initiative (CGCI) utilizes advanced genomic sequencing technologies to molecularly characterize cancer types, such as lymphoid and HIV-associated cancers. 2. The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative uses genome-based approaches to identify candidate therapeutic targets and biomarkers in childhood cancer patients with poor clinical outcomes. 3. The Cancer Target Discovery and Development (CTD2) Network applies high-throughput computational and functional biology approaches to validate genomic discoveries for rapid translation into patient-informed cancer treatments. To enhance its translational impact, OCG makes data, tools, reagents, and discoveries available to the research community. Visit http://ocg.cancer.gov to learn more.

back to top